Rankings
▼
Calendar
ICCC Q4 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena
ICCC
ImmuCell Corporation
$60M
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
+45.4% YoY
Gross Profit
$3M
47.0% margin
Operating Income
$145,412
2.7% margin
Net Income
$74,134
1.4% margin
EPS (Diluted)
$0.01
QoQ Revenue Growth
+5.7%
Cash Flow
Operating Cash Flow
$587,893
Free Cash Flow
-$116,701
Stock-Based Comp.
$40,931
Balance Sheet
Total Assets
$44M
Total Liabilities
$12M
Stockholders' Equity
$33M
Cash & Equivalents
$10M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$4M
+45.4%
Gross Profit
$3M
$2M
+58.0%
Operating Income
$145,412
-$634,000
+122.9%
Net Income
$74,134
$189,000
-60.8%
Revenue Segments
FirstDefenseProductLineMember
$5M
99%
OtherAnimalHealthMember
$40,595
1%
Geographic Segments
UNITED STATES
$4M
82%
OtherStatesMember
$984,574
18%
← FY 2021
All Quarters
Q1 2022 →